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CHAPTER I 
INTRODUCTION 
While data may be objectively “complete” and conforming regarding lists of 
known valid values, failure to check for contextual inconsistencies potentially result 
in data that is less efficient at leading to knowledge than it may appear, especially 
when data sets from different sources are integrated for secondary use.  To examine 
this problem and our proposed solution, we split our research into three distinct 
parts, which will be introduced in the three chapters throughout this paper. 
In our first of the related studies, we introduce a novel yet simple and fast 
method of increasing the quality of translational cancer research data.  The method 
is novel in that cross checking we label as a contextual method is used to measure 
data quality.  We compare the results to those of traditional methods of checking 
accuracy and completeness, something we label as an intrinsic method. 
In our second study, we introduce an algorithm and method to computationally 
identify contextual relationships within a dataset.  We compare the results to those 
using subject matter experts (SMEs), a gold standard in data quality efforts. 
Finally, we end this group of research with our third study.  In this case study, 
we apply our methods to two datasets, each meant to convey the same information 
but coming from different sources.  Then, we further test our methods by applying 
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them to a third dataset, the combination of the first two datasets, to see how well 
our methods identify the data quality of integrated data sets. 
Combined this set of studies investigates a novel method, involvement of SMEs, 
and data integration regarding translational cancer research data quality.  Our 
perspective is a focus on “translational cancer research data quality" due to each of 
its component parts’ overall relevancy to the subject. 
We focus on transitional research data quality because, as opposed to common 
knowledge, the knowledge flowing from research is knowledge that is in flux, 
evolving, and novel.  Translational medicine is a rapidly growing discipline in 
biomedical research and aims to expedite the discovery of new diagnostic tools and 
treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" 
approach [1].  The length of time this new data has been available for data quality 
testing, therefore, is less than that of established data. 
Furthermore, as a national medical priority, cancer research is relatively well-
funded [2]. With cancer research, so fueled, the data volume increase in this domain 
is high when compared to other data areas. 
We focus on data, of course, because the volume of data in general is increasing 
as computational power and speed increase [3].  Concurrently, storage capability is 
becoming both more efficient and more affordable.  
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We focus on data quality.  Tradition focuses on accuracy and completeness. 
However, with increased volume there is increased opportunity to acquiring 
confidence in the quality of a data set through cross-checking. Cronbach's alpha is a 
measure of internal consistency, that is, how closely related a set of items are as a 
group.    Cronbach's alpha can be written as a function of the number of test items 
and the average inter-correlation among the items.  Below, for conceptual purposes, 
we show the formula for the standardized Cronbach's alpha: 
 
Here N is equal to the number of items, c-bar is the average inter-item 
covariance among the items and v-bar equals the average variance.  One can see 
from this formula that if you increase the number of items, you increase Cronbach's 
alpha. 
 
ACRONYMS AND FRAMEWORK 
Acronyms referenced in this group of studies fall into one of two domains: oncology 
and health informatics.  Acronyms within the oncology domain include those for the 
terms: absolute lymphocyte (ALYM), natural killer [cell] (NK), absolute NK (ANK), 
complete blood count (CBC), Masonic Cancer Center (MCC), National Cancer Institute 
(NCI), Oncology Business Layer (OBL), Oncology Medical Informatics and Services 
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(OMIS), and white blood cell (WBC).  Acronyms within the health informatics domains 
include those for the terms: Common Data Elements (CDE), conditional functional 
dependency (CFD), electronic health record (EHR), information technology (IT), data 
quality (DQ), contextual DQ (CDQ), and intrinsic DQ (IDQ). 
We develop, describe, and apply two frameworks – the IDQ Framework and the 
CDQ Framework to expose and quantify DQ issues in three case studies.  Our IDQ 
Framework represents a traditional method to detecting DQ issues.  Categories of 
measures within this method include: missing data, i.e. incompleteness, and 
intrinsic inaccuracies.  Our CDQ Framework represents our proposed novel 
augmentation to traditional methods.  We compare the results of traditional DQ 
issue detection efforts augmented with our CDF method versus those from 
traditional methods alone.  Ultimately, our studies’ goal is to show that by utilizing 
the combined methodology, the quality of data, and as such the value, can be 
improved. 
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UNIFIED LITERATURE REVIEW 
Second only to heart disease, cancer is the leading cause of death worldwide [4].  In 
Taiwan, where cancer has become the leading cause of death since 1982, maintaining a 
high-quality cancer registry database is essential, and efforts have ensured completeness 
of this data at the level of 97% [5].  This focus on an intrinsic, non-contextual measure – 
accuracy – is not unusual.  Electronic validation of oncology clinical trial data is typically 
performed on isolated data elements at the transaction level, prior to data integration, 
around the time of data entry into a system, whether input is manual or automated (e.g. as 
in a transmission, or a health level 7 message).  Health data quality (DQ) studies have 
investigated diagnostic coding [6] and, other health data [7] [8]. DQ improvement efforts 
tend to focus narrowly on accuracy [9] [10] [11] and completeness [12] [13].  Accuracy-
related measures such as electronic sources matching electronic targets, precision, value 
within range, and allowed values, and completeness-related measures such as lack of 
missing values and completed required fields are typical measures of electronic DQ [12] 
[13].   These measures are intrinsic in nature since they are characteristic of a particular 
data item.  A potential shortcoming with this approach is a lack of contextual sensitivity. 
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The need for contextual sensitivity becomes greater for translational cancer research 
data considering the amount of data integration involved.  Researchers at the University 
of Arkansas, for example, understand that because clinical research data is the output of a 
federation of collection mechanisms and systems, there is an increased risk of poor data 
quality leading to inefficient use of research data, or the need for costly repetition of 
clinical studies [14].  The researchers present two tools for improving data quality of 
clinical research data relying on the National Cancer Institute’s Common Data Elements 
(CDE) as a standard representation of possible questions and data elements to A: 
automatically suggest CDE annotations for already collected data based on semantic and 
syntactic analysis utilizing the Unified Medical Language System (UMLS) Terminology 
Services’ Metathesaurus and B: annotate and constrain new clinical research questions 
though a simple-to-use “CDE Browser.”  The results showed that a small portion of 
suggested annotations were syntactically and semantically sound; however, many of the 
results were complete misses. Lacking in the researchers’ approach was a way to 
establish sensitivity to context. 
Our three studies build on past efforts to provide automated data quality assessment, 
improvement, and constraints for clinical research data, by first confirming the 
importance of context sensitivity to data quality efforts, next by exploring a way to 
automate context sensitivity, and finally by testing the application of context-sensitive 
data quality assessment to federated data. 
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CHAPTER II: CONTEXTUAL VS. INTRINSIC EVALUATION OF 
CANCER RESEARCH DQ 
Giordi Orreggio, MHI1, Sarah Cooley, MD1, Stuart Speedie, PhD2 
1Masonic Cancer Center, University of Minnesota, Minneapolis, MN;  
2Institute of Health Informatics, Minneapolis, MN 
 
SYNOPSIS 
Traditional data quality (DQ) efforts focus on intrinsic measures, such as accuracy 
and completeness.  Translational research in oncology relies heavily on integration of 
routine patient care data with research laboratory generated data.  The repurposing of 
such data for research use raises the risk of introducing contextual DQ (CDQ) issues. 
CDQ issues include logical inconsistency and improbable distributions of data element 
values.  Methods were developed to assess the CDQ of 6442 absolute natural killer cell 
(ANK) blood sample collection records.  This paper highlights this specific example to 
present a novel method of exposing DQ issues.  Compared to traditional intrinsic tests of 
DQ, which exposed problems in 1161 (18%) of the records, CDQ testing exposed an 
additional 3177 records, or 4338 (67%) records with some concern about data quality. 
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INTRODUCTION 
Electronic validation of oncology clinical trial data is typically performed on isolated 
data elements at the transaction level, prior to data integration, around the time of data 
entry into a system, whether input is manual or automated (e.g. as in a transmission, or a 
health level 7 message).  Health data quality (DQ) studies have investigated diagnostic 
coding [6] and, other health data [7] [8]. DQ improvement efforts tend to focus narrowly 
on accuracy [9] [10] [11] and completeness [12] [13].  Accuracy-related measures such as 
electronic sources matching electronic targets, precision, value within range, and allowed 
values, and completeness-related measures such as lack of missing values and completed 
required fields are typical measures of electronic DQ [12] [13].   These measures are 
intrinsic in nature since they are characteristic of a particular data item. 
One cannot assume that if the data appears to be intrinsically accurate and complete at 
time of entry, the quality of repurposed and integrated data will be optimal.  The problem 
regarding translational oncology research is that because this domain relies heavily on 
integration of repurposed routine patient care data with research data, intrinsic methods 
fall short. As data collected for patient care is reused for a different purpose (research), 
this raises the risk of contextual DQ issues developing. 
To understand the difference between an intrinsic characteristic and a contextual 
characteristic, consider that mass is a physical intrinsic property of any physical object, 
weight is a contextual property that varies depending on the strength of the gravitational 
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field in which the respective object is placed.  When DQ is perceived as fitness for use, 
the DQ is defined contextually by the user’s requirements.  CDQ issues include logical 
inconsistency of information and improbable distribution of data element values. 
It is generally inadvisable to make assumptions about a dataset derived from another 
[11].  Past study of electronic health record (EHR) DQ has revealed highly variable 
results.  Hogan and Wagner [15] in their 1997 literature review found that the accuracy of 
data ranged between 44% and 100%, and completeness between 1.1% and 100%, 
depending on the clinical concepts being studied.  In a medical setting, DQ issues may 
lead to decreased care quality, introduce privacy and other civil liberty concerns, create 
liability risks, undermine the reliability and benefits of information technology (IT) 
investments, deter adoption of health IT, and cost lives [16].  Systematic methods of 
assessing the quality of an EHR-derived dataset for subsequent research tasks are needed. 
While traditional DQ efforts primarily examine data elements intrinsically, data 
collected for translational research studies integrated with data collected as part of patient 
care is at risk of CDQ issues.  Integrated data has the potential to be more informative 
with respect to DQ than the sum of its isolated elemental constituents.  One data element 
can be cross-checked against another for logical consistency within the context of co-
existing data elements with a data set, or used as raw data to calculate new data elements. 
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THE IDQ FRAMEWORK 
Missing fields and missing values are among the subtypes of the intrinsic data quality 
(IDQ) threat incompleteness.  When rows from two different data sources are 
concatenated into one table, and one data source contains a column that is not contained 
in the other data source, the resulting integrated data will have a missing field for each 
row that originated from the data source that could not supply the field.  A missing value 
occurs when a field (storage for a variable value) exists, but no data value is stored for the 
variable in an observation.  Possible causes of a missing value include: 
• Programming error 
• Inadvertent data entry omission 
• Optional field 
• Nonconformance regarding required fields 
• Data entry is pending 
Both missing fields and missing values result in incompleteness, i.e. missing data.  
Missing data are a common occurrence and can have a significant effect on the 
conclusions that can be drawn from the data.  All data elements are vulnerable to 
incompleteness.  Missing data can usually be programmatically detected by querying for 
“Null” values. 
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Other intrinsic DQ threats involve data which exist but is inaccurate.  An inaccuracy 
occurs when a field exists, and a value is stored for the variable in an observation, but the 
statement is in fact erroneous.  Inaccuracy threats include: 
• Date of actual occurrence is in the future 
• Numeric value out-of-specified-range 
• Categorical value not part of a specified set of allowable values 
• Formatted text value does not conform to specified format 
• Generally erroneous data 
Data-type-based threats can usually be programmatically detected by queries based 
on established business rules.  However, IDQ assessment techniques do not effectively 
detect the last threat, erroneous unformatted text data.  Possible causes of inaccurate data 
include: 
• Programming errors 
• Data entry error 
• Differing units within the same lab test 
• Preliminary data entry to be subsequently updated 
• Data dictionary is lacking or not available 
• Data dictionary is not adhered to 
• Guidelines are not adhered to 
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• Unclear data definitions 
• Unclear data collection guidelines 
 
THE CDQ FRAMEWORK 
Where intrinsic DQ assessment techniques fail, CDQ assessment techniques may 
succeed.  A contextual perspective may expose a data value which intrinsically appears 
true, but is not.  Any combination of the previously listed causes may result in threats to 
CDQ threats. Data profiling of integrated data uniquely enables identification of 
contextual DQ threats including logical inconsistency, low cardinality, and anomalous 
distribution. 
A logical inconsistency is logical incompatibility or contradiction between two or 
more statements.  Each value of two associated attributes may appear accurate when 
examined intrinsically, but juxtaposed may expose previously undiscovered problems.  
Despite the absence of any DQ issues in the individual data elements, their integration 
can create significant errors resulting from subtle and minor discrepancies in business 
rules between multiple sources.  For example, while each data element has a specific set 
of values prior to integration, a new specified set of values is created for the composite 
data element.  Thus, an opportunity exists to query based on those business rules to test 
for logical inconsistency.  Chiang and Miller call these conditional functional 
dependencies (CFDs) [17]. 
  
 13 
For a category to be useful, it should contain a minimum number of records.  The 
more categories there are, the more information there is available for review and 
summarization [18].  However, too many categories, while adding complexity, may not 
add useful detail.  Although the number of categories that is too many may be subjective, 
each categorical data element that does not exhibit low-cardinality potentially contains 
too many categories.  Low-cardinality refers to columns with few unique values. Low-
cardinality column values are typically status flags, Boolean values, or major 
classifications such as gender.  Thus, a low cardinality violation occurs when a 
categorical data element contains a significant quantity of unique values. 
Low cardinality alone does not guarantee high utility.  One or two records may 
include something quite intriguing, but if they are one or two out of 1,000 records, the 
information they contain may not be frequent enough in the population to be practically 
useful [18].  Distribution analysis of categorical data may reveal data that threatens value 
not with inaccuracy, but with usability challenges.  Distribution analysis of numeric data 
elements can often be compared to an expected distribution.  Such comparison might 
reveal that a data value which intrinsically appears accurate, contextually appears as an 
outlier or anomaly and worthy of explanation.  An investigation may lead to detection of 
a data error, refinement of business rules, or scientific discovery.  A numeric data value 
may appear as an outlier or as a data statistical distribution anomaly, when compared to 
the entire available population of values for the same data element.  A data anomaly is a 
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value or set of values failing to conform to an expected (or useful) pattern [19], e.g. a 
statistical distribution pattern. 
Distribution analysis is not typically informative regarding data that are not numeric 
or categorical.  For each numeric or categorical data element, however, a histogram of its 
population of values can be created to visualize its distribution and visually detect 
outliers and nonconformance to the expected pattern.  The Pareto principle (also known 
as the 80–20 rule, the law of the vital few, and the principle of factor sparsity) states that, 
for many events, roughly 80% of the effects come from 20% of the causes [20].  
Usability may be better supported when: 
• 80% of an element’s instances are attributed to 20%+ of the categories 
• 80% of an element’s categories contribute to 20%+ of the instances 
Partitioning each histogram in quintiles to apply the Pareto principle may help to 
expose perceived defects and outliers.  The Pareto Principle, however, is not an 
established scientific theorem, but rather an operational heuristic.  Researching different 
partitioning methods may be beneficial. 
The goal of our work is to apply this simple and easily reproducible framework to 
examine the value of datasets with intrinsic and contextual methods.  The hypothesis of 
this study is that in addition to traditional/standard methods to measure IDQ, the 
application of additional CDQ methods to ANK related data will detect more DQ issues.  
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THE DATA SOURCE 
This study focused on the oncology domain and the calculation of natural killer cell 
counts as the context. If the absolute lymphocyte count (ALYM) of a blood sample is 
known, and the percentage of those ALYMs which are natural killer (NK) cells are 
known, the absolute count of NK cells (ANK), an outcome of many oncology clinical 
trials, can be calculated (ANK [cells/uL blood] = ALYM [cells/uL blood] x % of 
lymphocytes which are NK cells).  NK cells are lymphocytes which play an important 
role in the innate immune response to infection and cancer and are studied extensively as 
potential therapeutic agents.  The data was obtained from the Masonic Cancer Center 
(MCC) which is one of 41 certified comprehensive cancer centers nationwide, and one of 
two in Minnesota, as recognized by the National Cancer Institute (NCI) (National Cancer 
Institute).  MCC’s Oncology Medical Informatics and Services group (OMIS) develops 
and maintains MCC’s repository of oncology clinical trial integrated data called the 
Oncology Business Layer (OBL).  The OBL has accumulated health data for more than 
2,000 clinical research protocols and 10,000 subjects treated for cancer as early as 1968.  
Data from clinical, protocol management, flow cytometry, molecular cell therapy, bio-
repository, and bone marrow transplant information systems are copied nightly to a 
landing area where general extract/transform/load processes are run to populate the OBL. 
The OBL is where the raw data necessary to calculate ANK is first integrated.  The 
data collection process for each subject begins when a cancer patient at a hospital 
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(typically at the University of Minnesota Medical Center Fairview, but sometimes 
another institution) is enrolled as a subject in one or more MCC clinical research trials.  
A hospital typically collects blood samples from each patient (typically daily but 
sometimes more frequently) for complete blood count (CBC) testing as part of patient 
care and without regard to any research protocol.  Included in CBC results are those for 
ALYM and those for white blood cell (WBC) count.   For each patient who is also a 
subject, available test results are electronically transmitted to the OBL.  For each subject, 
at specific time points determined by a research protocol calendar, a separate processed 
blood sample associated with a Patient Identifier and a Collection Date is sent to MCC’s 
research laboratory for additional testing.  The processed sample cannot be used to 
determine ALYM or WBC levels.  The research laboratory’s test results are also 
electronically transmitted to the OBL, and include the % of lymphocytes which are NK 
cells (%NK).  To calculate ANK, for each %NK numeric test result, its associated Patient 
ID and Collection Date pair are used to match to ALYM and WBC results to link each 
%NK result to all ALYM and WBC results collected for that patient on that date. MCC’s 
total populations of 6442 ANK blood sample collection records were this obtained over a 
period from 2003 to 2013. 
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APPLICATION OF THE IDQ FRAMEWORK TO ANK DATA 
IDQ assessment methods listed in Table 1 were applied to each variable; %NK, 
Collection Date, Patient ID, and ALYM to identify IDQ issues.  Each variable was also 
evaluated for completeness.  The value of each numeric data element (in this case %NK 
and ALYM) was examined for whether it fell within an expected range.  If it fell outside 
of the range, both the numeric value and record containing the value was marked as 
having an IDQ issue.  Because %NK is a value representing a percentage, the expected 
range for %NK must be from 0 to 100.  The expected range for ALYM was 0 to 1054 per 
mL of blood, the largest value recorded.  Collection Date was tested for a date which was 
logical.  If the date was in the future, both the date and the record containing it was 
marked as having an IDQ issue.  Patient ID (text) was examined to determine whether it 
was in the expected format for MCC.  The expected format of the patient identifier was 
either a ten-character hospital medical record number (MRN) or an OMIS-generator 
identifier containing the characters “KIR.”. 
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IDQ Framework 
 Data Element 
Name 
Data 
Type 
IQD Test 
Type IDQ Data Element Test Rule 
%NK 
Nume
ric Valid range 0-100 
Collection 
Date Date Logical date Not future-dated 
Patient ID Text 
Consistent 
format 
10 characters long or contains 
characters “KIR” 
ALYM 
Nume
ric Valid range 0-1054 
Table 1. The IDQ Framework applied to ANK data. 
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APPLICATION OF THE CDQ FRAMEWORK TO ANK DATA 
The CDQ framework was used to develop and apply CDQ methods for each data 
element (Table 2).  Each same row of data was further evaluated and flagged as 
containing a CDQ issue, if it had a calculated ANK result outside the range of 0 to 1054, 
an ALYM result greater than its associated WBC result, and/or no ALYM result paired 
with an existing %NK result.  Descriptive statistics for CDQ versus IDQ issues are 
presented in the Results section. 
 
CDQ Framework 
 Data Element 
Name(s) CQD Test Type CDQ Case Rule 
ALYM, WBC 
Logical 
Consistency 
WBC >= ALYM from the 
same blood sample collection 
%NK, ALYM 
Logical 
Consistency 
At least one ALYM exists 
when a %NK exists for the same 
patient on the same collection date 
ANK=%NK*ALYM/
100 Valid Range 0-1054 
Table 2. The CDQ Framework applied to ANK data. 
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STUDY RESULTS 
 
 
Records 
exposed 
contextually, 
but not 
intrinsically 
Records 
exposed 
intrinsically, 
but not 
contextually 
All 
records that 
were 
exposed 
intrinsically 
All 
records that 
were 
exposed 
contextually 
All 
records 
IDQ Results 
Count of %NK 3177 0 1161 4338 6442 
Count of %NK Out-
of-Range  0 0 0 0 0 
Count of Patient ID 3177 0 1161 4338 6442 
Count of Patient ID 
Inconsistent Format 0 0 720 720 720 
Count of Collection 
Date 3177 0 1161 4338 6442 
Count of Collection 
Date Invalid  0 0 0 0 0 
Count of ALYM 1 0 444 445 2549 
Count of ALYM Out-
of-Range  0 0 444 444 444 
Count of Records 
with at least 1  0 0 1161 1161 1161 
CDQ Results 
Count of WBC 453 0 0 451 2552 
Count of 
ALYM>WBC 1 0 0 1 1 
Count of Missing 
%NK link to ALYM 3176 0 717 3893 3893 
Count of ANK 1 0 444 445 2547 
Count of ANK Out-
of-Range 0 0 444 444 444 
Count of Records 
with at least 1 3177 0 1161 4338 4338 
Table 3. Complete DQ results. 
The CDQ Framework revealed 3177 DQ issues above and beyond what could be 
detectable through intrinsic methods.  The majority (3176) of these issues were 
contextually exposed by cross-referencing each %NK value with its associated ALYM 
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value and flagging an error if unsuccessful.  The other 1 was contextually exposed by 
cross-referencing each ALYM value with its associated WBC value (Table 3). 
No issues were exposed intrinsically, that were not also exposed contextually.  After 
applying the IDQ Framework to the ANK data, no result for %NK was found to be 
beyond the valid range (0-100), and no Collection Date was found to be a date in the 
future.  However, 720 Patient IDs were found to be malformed, and 444 ALYM values 
were found to be beyond the valid range, 0-1054.  Using the IDQ Framework, a total of 
1161 out of 6442 (18%) sample collection records were flagged has having at least one 
IDQ issue.  The same 1161 records were flagged contextually through two distinct CDQ 
tests.  444 ANK calculations were beyond the valid range, 0-1024, and 717 [%NK] 
collections lacked an association to an ALYM test result (Table 3).  
Using the IDQ Framework, a total of 1161 out of 6442 (18%) sample collection 
records were flagged has having at least one IDQ issue.  Applying the CDQ Framework 
to the same 6442 records, 4338 (67%) records were flagged as having at least one issue 
by 3 distinct CDQ tests.  446 ANK calculations were beyond the valid range (0-1024), 3 
ALYM results were erroneously greater than their associated WBC result, and 3893 
[%NK] results lacked an association to at least one ALYM test result (Table 3). 
DISCUSSION 
CBCs (including ALYM and WBC) are processed in a hospital from MCC clinical 
trial subjects as part of routine patient clinical care.  An evaluation of this clinical data 
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would reveal that the data was complete (i.e. containing no missing values) when all 
results were found for all tests that should have been taken according to the current 
prevailing standard of care. 
Separately, immune monitoring tests (including %NK) are processed in MCC’s 
research laboratory for each of the same MCC clinical trial subjects as determined by a 
specific research protocol.  An evaluation of this research data would reveal that the data 
was complete when all results were found for all tests that should have been taken as 
specified by each test’s governing protocol. 
CDQ assessments identify issues with integrated data that cannot be found 
intrinsically 
The majority (3176) of records flagged contextually that were not flagged 
intrinsically were those where a %NK value existed, but an associated ALYM value did 
not exist.  Only after integrating the ALYM data with the %NK data from the research 
lab, can this be evaluated in the context of ANK calculation.  This study therefore 
considers this DQ issue one that is contextual.  Possible reasons for the missing ALYM 
values include incorrectly entered subject identifiers in the system which sources the 
%NK values preventing a linkage the ALYM value in the clinical source, or a problem 
with the integrity of transmission of the source system to the target destination, the OBL. 
The remaining one issue was contextually exposed by cross-referencing each ALYM 
value with its associated WBC value and testing the values to see whether the ALYM 
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was less than or equal to its associated WBC.  For both values to be accurate, this must be 
the case, because lymphocytes are a subset of white blood cells.   However, this ALYM 
of 0.4 was associated with a WBC of 0.2.  0.4 and 0.2 are valid values intrinsically for 
ALYM and WBC respectively, yet one or both values is clearly erroneous when 
juxtaposed, making this case a classic example of the need for contextual testing.  Data 
entry error is the likely cause of this CDQ issue. 
Issues exposed intrinsically are also exposed contextually 
Pre-study expectations were that intrinsic methods would identify some DQ issues, 
contextual methods would identify more, but the two sets of results would be 
overlapping.  In other words, it was expected that intrinsic methods would detect issues 
that would not be detected contextually. Surprisingly, no issue was found intrinsically 
that was not also found contextually.  
444 ALYM values were intrinsically found to be beyond the valid range, 0-1054.  
While most CBC data was sources from Fairview, a subset of CBC data was sourced 
from one other source.  All 444 out-of-range ALYM values were found to be from this 
source.  Differing rules between the two sources regarding the units used for ALYM 
accounted for discrepancy.  Fairview entered ALYM values in cells/uL blood, while the 
ALYM values from the non-Fairview source appeared to be entered in cells/mL blood 
resulting in numbers 1,000,000x greater than they should have been.  For each %NK 
result, its associated Patient ID sourced from the research laboratory was intrinsically 
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tested.  720 Patient IDs were found to be in a format other than what was expected at 
MCC.  Data entry error is a possible cause.  The impact of a poorly formatted Patient ID 
is the potential inability to link to CBC data which is from a source other than the 
research laboratory.  Only 3 of these IDs successfully matched one associated with an 
ALYM result, but the 3 ALYM results were among those the 444 that were intrinsically 
found to be out-of-range.  Thus, 444 and an additional 717 records were flagged 
intrinsically for a total of 1161. 
The same 444 records that were flagged intrinsically were also flagged contextually 
by testing each ANK value to see whether it was within the expected range, 0-1054.   717 
failed the CDQ test for linking each %NK results to one or more ALYM result. Thus, the 
same 1161 intrinsically flagged records were also flagged contextually. 
 
CONCLUSION 
CDQ assessments identify more issues with integrated data 
Within the domain of translational oncology research, the importance of assessing the 
intrinsic quality of electronic health data is well recognized.  With increasing exchange 
and secondary use of data, now more than ever segmented information must be integrated 
from multiple entities.  Therefore, the primary goal of this study was to explore the 
hypothesis that the addition of contextual methods of assessing the quality of translational 
oncology research data is more effective than intrinsic methods alone.  This study 
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developed simple frameworks to apply traditional IDQ measures and to create novel 
CDQ measures for oncology research data elements.  Each of the two frameworks was 
then applied the same test dataset, using calculated ANK counts, to compare the 
effectiveness of the two approaches to DQ.  In contrast to intrinsic methods alone, the 
addition of contextual methods increases the number of DQ issues detected.  
Furthermore, the CDQ framework captured 100% of the issues that were identified by the 
IDQ framework.  This example demonstrates that the framework can be applied to 
translational oncology research data to enhance the quality and ultimately support better 
research for the development of new treatments for cancer. 
Limitations to this study include using one case study, examining of a small number 
set of data elements, and the utilization of no more than three data sources.  The data 
examined within this study also did not test all the components of the proposed 
frameworks including examining data element distribution anomalies and categorical 
data.  Finally, results were not analyzed in terms of dimensions such as time, gender, or 
disease.  These limitations were useful in meeting the study goal of developing and 
implementing a simple and reproducible pair of DQ frameworks.  Future work may 
address these limitations, while building upon the work presented here.   
Traditional DQ efforts are intrinsic in nature.  This represents a gap in the domain that 
is worthy of additional exploration.  Global analysis, visualizations, and descriptive 
statistics represent a potentially powerful framework for assessing the quality of 
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integrated oncology research data, and ultimately improving patient care.  DQ issues 
within oncology data collected for translational research combined with secondary use of 
data collected during clinical treatment may better be detected with novel methods that 
take into consideration the context. 
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CHAPTER 3: PROFILING VS. SME RECALL IN DEFINING 
RULES FOR TRANSLATIONAL CANCER RESEARCH DATA 
QUALITY 
Giordi Orreggio, MHI1, Sarah Cooley, MD2, Stuart Speedie, PhD1  
1Institute of Health Informatics, Minneapolis, MN 
2Masonic Cancer Center, University of Minnesota, Minneapolis, MN 
 
 
SYNOPSIS 
Translational cancer research relies heavily on data collected longitudinally about 
subject visits and subsequent clinical outcomes.  The context of the single data point is 
often not yet defined at the time of data entry, which raises the risk of introducing 
conditional functional dependency (CFD) inconsistencies. Many tools for constraining 
data using rules to detect CFD inconsistencies exist, but little guidance is available 
regarding how to determine such rules.  We compared the results of CFD rules generated 
by subject matter experts (SME) recall to CDF rules generated by data profiling. Data 
profiling identified three more CFD rules than the seven previously defined by subject 
matter expert (SME) review.  Since confirmation of previously identified CFDs 
motivated reanalysis and rule modification, data profiling appears to be useful for 
confirming data rules documented by SMEs.  Using both SMEs and data profiling results 
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in a better understanding of rules for determining data quality of translational cancer 
research data. 
 
SIGNIFICANCE 
Past studies of electronic health record (EHR) data quality (DQ) have revealed highly 
variable results.  Hogan and Wagner [15] in their 1997 literature review found that the 
accuracy of data ranged between 44% and 100%, and completeness between 1.1% and 
100%, depending on the clinical concepts being studied.  In a medical setting, DQ issues 
(DQIs) may lead to decreased care quality, introduce privacy and other civil liberty 
concerns, create liability risks, undermine the reliability and benefits of information 
technology (IT) investments, deter adoption of health IT, and cost lives [16]. 
Data rules can be used to test and evaluate data quality.  Data rules provide a method 
to define specific tests (i.e. validations and constraints) associated with data, and identify 
exceptions to expected conditions.  Such rule application or tests may evaluate to a true 
or false value to set up pass or fail checks to assess DQ. They represent logical 
expressions that can include multiple conditional expressions, and they can contain 
simple or complex and nested Boolean conditions [21]. 
Current DQ improvement efforts tend to focus on accuracy [9] [22] [23] and 
completeness [24] [13].  Accuracy-related measures such as precision, value within 
range, and allowed values, and completeness-related measures such as missing values are 
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typical measures of DQ [24] [13].  We label these intrinsic measures.  Because our area 
of research, translational cancer research, relies heavily on data collected over time about 
subject visits and subsequent clinical outcomes, intrinsic data quality (IDQ) approaches 
alone that focus on individual data items independent of all others may fall short of 
characterizing the quality of the data.   
For example, when an instance of a required data element called Gender is “Male” 
and an instance of a required data element called Cancer Site is “Ovary” for the same 
patient, while the values are both valid and not missing, they are logically inconsistent 
with each other, given the rule that males are not known to have ovaries.  Chiang and 
Miller [17], and Bohannon and Fan [25] among others, call these conditional functional 
dependencies (CFDs).  They believe that in contrast to traditional functional 
dependencies that were developed mainly for schema design, CFDs aim at capturing the 
consistency of data by incorporating bindings of semantically related values.  This not 
only yields a constraint theory for CFDs but is also a step toward a practical constraint-
based approach for improving DQ. 
 
PREVIOUS STUDY 
Our previous study of contextual vs. intrinsic evaluation of DQ [26] demonstrated 
that translational cancer research data element instances appearing to have no intrinsic 
data quality issues (IDQIs) could have conditional functional dependency inconsistencies 
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(CFDIs), a contextual data quality issue.  In that study, data rules were defined directly 
using subject matter expert (SME) recall [27].  Our CFDI framework defined a simplified 
process of pairing each candidate data element with another candidate data element and 
relying on a SME to determine whether one or more testable CFDs are applicable. 
As a validation process, results from these preliminary tests can then be analyzed to 
determine whether it an actual potential error, or an effect of a misunderstanding of the 
associated rules.  When a detected CFDI is deemed to be a false positive, a new 
understanding of a rule is gained, associated tests can be modified, and the process can be 
repeated until all the rules applied appear plausible and valid. 
For example, in our previous study, users of blood and bone marrow transplant 
(BMT) cellular product infusion data generally believed that an acceptable intrinsic rule 
for the Recipient BMT Identifier (ID) is that it is to be formatted as an 8 characters value, 
beginning with 4 digits and ending with 4 alphabetical characters.  Based on this rule, 
initial testing of Recipient BMT ID resulted in 108 “malformed” values.  However, upon 
further examination, patterns in these Recipient BMT IDs suggested intentional deviation 
from a default format, rather than entry errors.  After reiteration and refinement for the 
final analysis a modified IDQ rule and also an additional CFD rule were applied, each 
more complex than the initial IDQ rule.  Similarly, the rule for Donor BMT ID is 
believed to be a value that is “null” or 8 characters long, beginning with 4 alphabetical 
characters and ending with 4 digits.  Based on that rule, the original IDQ testing for 
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Donor BMT ID resulted in 70 “malformed” Donor BMT IDs.  After initial inspection, 
however, the original simple initial IDQ rule for Donor BMT ID was replaced by a 
different IDQ rule and an additional CFD rule.   
In our previous study, we defined logical inconsistency as logical incompatibility or 
contradiction between values of two or more data elements.  Our CFDI testing 
conceptually constrains one or more values of one data element to one or more values of 
another data element within the same case, testing logical consistency and enumerating 
CFDIs.  We defined a simple process of pairing each data element that is a candidate for 
examination with every other candidate data element and then, for each pairing, relying 
on existing subject matter expertise to determine whether one or more testable CFDs for 
that pair existed. Each resulting CFD was incorporated into a rule for logical 
inconsistency regarding that data element pair.  This resulted in three SME-identified 
CFDs that paired categorical data as shown in Table 1.  
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Conditional Functional Dependency 
Inconsistency (CFDI) 
Rule 
inconsistent  
Donor Relationship -> Product 
Relationship 
"Self" -> "Autologous" 
"Not entered" -> "Not entered" 
Any other -> not "Autologous" 
inconsistent  
Product Type -> Donor CMV Status 
A cord blood -> not 
"Positive" 
Any other -> any 
inconsistent  
Product Type -> Product Relationship 
"Not entered" -> "Not 
entered" 
A cord blood -> "Allogeneic" 
“NK (Natural Killer) Cells” -> 
Allogeneic 
“Cellerant Therapy” -> 
Allogeneic 
Any other -> not "Not entered" 
Table 4: Our CFDI framework applied in our previous study producing three CFDIs 
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BACKGROUND 
While our previous study suggested that this approach was effective at increasing 
both the understanding of data element pair relationships and the detection of CFDI, it 
did not account for the possibility that not all rules were discovered.  An alternative to 
relying on SME recall is to expose relationships between data element pairs from data 
profiling results [27].  One data element’s dependency on another influences the 
distribution of values within the two data elements.  For categorical data elements, this 
effect can be meaningfully quantified since the number of discrete categories is generally 
small.  It is less applicable to data elements with a large range of values such as dates, 
identifiers and numeric measures. 
Consider an example where the unique values of a data element called Cancer Site 
{Ovary, Prostate, and Lung} and the unique values of a data element called Gender are 
{Female and Male}.  The minimum number of possible unique combinations of the two 
data elements is the number of unique data element values (cardinality) of whichever set 
is larger, in this case, 3.  Each value of the first data element paired with each value of the 
second data element produces the maximum number of possible unique combinations, in 
this case, 6.  In the absence of a rule linking the two component data elements, we would 
expect to observe a number of unique combinations closer to the maximum.  On the other 
hand, given the rule that {Prostate} applies to males only and {Ovary} to females only, 
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we would expect to observe 4 actual unique combinations.  This count of 4 on a scale of 
3 to 6 where 3 is 0% and 6 is 100% can be represented as 33%, i.e. the two data elements 
are more dependent than not. 
Although two data elements may have a degree of dependency, an extremely low 
independence value (as calculated above) does not always suggest the existence of a 
testable rule.  Extremely low independence is also seen when a data element with high 
cardinality is involved.  High cardinality refers to the situation where a data element’s 
values tend to be unique as in numeric data, ordinal data, a date or an ID.  For example, 
observing the pairing of one value a data element to one ID or a minority of IDs within a 
dataset is more likely than observing the pairing of the one value to all IDs or most IDs 
within the dataset. Thus, our distribution test of independence is designed to be effective 
at suggesting the existence of a testable data rule in categorical data only. 
Similar cross-tabulation techniques are used by Cramer’s V to test the independence 
of two categorical data elements, and by other chi-square-related statistics. However, 
there are numerous limitations of these statistics. Some require a minimum sample size, 
or have a maximum number rows and columns in a table.  Others lack comparability 
between tables of different sizes.  Most require some statistical expertise.  Out technique 
is simpler to use and appears to detect the existence of data dependencies that can be used 
to generate rules to some degree. 
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We attempted to answer the research question, “Is information about data rules 
improved when a computational approach involving data profiling is added to SME 
recall?”  Our main experiment, therefore tests the hypothesis that translational cancer 
research data element instances that appear to have no CFDIs from a subject matter 
expert’s perspective can have CFDIs exposed by such computational approaches. 
 
METHODS 
Step 1 – Select the data targeted for analysis 
The data were obtained from the Masonic Cancer Center (MCC) which is one of 41 
certified comprehensive cancer centers nationwide, and one of two in Minnesota, as 
recognized by the National Cancer Institute (NCI) [28].  MCC’s Oncology Medical 
Informatics and Services group (OMIS) develops and maintains MCC’s repository of 
oncology clinical trial integrated data called the Oncology Business Layer (OBL).  The 
OBL has accumulated health data for more than 2,000 clinical research protocols and 
10,000 subjects treated for cancer since 1968.  The OBL is updated daily with data from 
clinical, protocol management, flow cytometry, molecular cell therapy, bio-repository, 
and blood and bone marrow transplant (BMT) information systems. 
As defined in Table 5, we focused on the categorical data elements reported for all 
cellular product infusions.  These data contain a representative sample of the kind of 
information that is often most important to the translational cancer researcher, patient 
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clinical outcomes and factors which are suspected to contribute to those outcomes. The 
combination of a Recipient BMT identifier (ID) and Infusion Number uniquely 
identifies each cellular product infusion. 
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Data Element 
Name 
Data Element Definition 
Diagnosis Type Name of the disease (the first local diagnosis) 
Donor CMV 
Status 
Serostatus result of donor collected prior to transplant of 
test for cytomegalovirus-specific IgG showing prior 
exposure to CMV 
Product Type Category of cellular product being infused 
Product 
Relationship 
Category of cellular product in terms of genetic 
sameness to recipient 
Recipient CMV 
Status 
Serostatus result of recipient collected prior to transplant 
of test for cytomegalovirus-specific IgG showing prior 
exposure to CMV 
Donor 
Relationship 
Relationship of donor to the recipient 
Table 5: The categorical data elements associated with all cellular product infusions 
Step 2 – Count the number of unique values found for each data element 
We counted the unique values existing for each of the categorical data elements, so 
that we could percentages of independence. 
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Step 3 – For each pair of data elements, calculate the percentage of 
independence 
We paired each of the six selected cellular product infusion data elements with each 
other and then: 
• Determined the minimum possible number of unique combined values 
resulting from each pairing (the largest count of the two component data 
elements) 
• Counted the actual unique combined values resulting from each pairing 
• Determined the maximum possible number of unique combined values 
resulting from each pairing by multiplying the two component data elements 
• For each pairing, applied an algorithm to calculate the two component data 
elements’ percentage of independence defined as the standardized measure of 
the actual unique combined values on a scale ranging from 0%, representing 
the minimum possible number of unique combined values to 100% 
representing the maximum possible number of unique combined values.  
Step 4 – Compare percentage of independence with functional 
dependencies previously defined by SMEs 
We predicted that each data element pair both involving only categorical data 
elements and appearing to be more dependent than not (scoring less than 50% 
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independent) would have a CFD that could be associated with an explanatory rule.  For 
such cases, we brought the relationships to the attention of an SME for additional review 
to either define a rule if it did not previously exist, or if it did, confirm or modify the rule. 
 
RESULTS 
As reported in  
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Donor 
Relationship 14 Product Type 18 18 72 252 23 
Donor 
Relationship 14 
Product 
Relationship 6 14 33 84 27 
Product 
Relationship 6 Product Type 18 18 49 108 34 
Diagnosis Type 16 
Donor 
Relationship 14 16 101 224 41 
Diagnosis Type 16 Product Type 18 18 145 288 47 
Donor CMV Status 5 Product Type 18 18 52 90 47 
Diagnosis Type 16 
Product 
Relationship 6 16 55 96 49 
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The element pairs above are dependent, while the pairs below are independent. 
 
Donor Relationship 14 Recipient CMV Status 5 14 42 70 50 
Donor CMV 
Status 5 
Donor 
Relationship 14 14 44 70 54 
Product Type 18 
Recipient CMV 
Status 5 18 63 90 63 
Diagnosis Type 16 
Recipient CMV 
Status 5 16 57 80 64 
Diagnosis Type 16 
Donor CMV 
Status 5 16 58 80 66 
Donor CMV 
Status 5 
Product 
Relationship 6 6 22 30 67 
Product 
Relationship 6 
Recipient CMV 
Status 5 6 22 30 67 
Donor CMV 
Status 5 
Recipient CMV 
Status 5 5 20 25 75 
Table 6, the categorical data element pairs scored within the range from 23% to 75% 
for independence: 
• 4 completely new CFDs were discovered (shown in  
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• 3 others were confirmed modified (shown in  
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Diagnosis 
Type 16 
Product 
Relationship 6 16 55 96 49 
 
The element pairs above are dependent, while the pairs below are independent. 
 
Donor 
Relationship 14 
Recipient CMV 
Status 5 14 42 70 50 
Donor CMV 5 Donor 14 14 44 70 54 
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Status Relationship 
Product Type 18 
Recipient CMV 
Status 5 18 63 90 63 
Diagnosis Type 16 
Recipient CMV 
Status 5 16 57 80 64 
Diagnosis Type 16 
Donor CMV 
Status 5 16 58 80 66 
Donor CMV 
Status 5 
Product 
Relationship 6 6 22 30 67 
Product 
Relationship 6 
Recipient CMV 
Status 5 6 22 30 67 
Donor CMV 
Status 5 
Recipient CMV 
Status 5 5 20 25 75 
Table 6: Percentage of independence between pairs of data elements, previously defined CFDs 
bolded and new CFDs grayed and bolded 
Results show that between each of the 2 data elements in the 3 previously defined CFDs there is low 
independence (27-47%).  Regarding the 4 new CFDs, Diagnosis Type specifically appeared to be 
associated with Donor Relationship, Product Relationship, and Product Type.  Product Type appeared to 
be associated with Donor Relationship.  Regarding the two newly modified CFDs, we discovered Donor 
Relationship -> Product Relationship, and Product Type -> Product Relationship our previous research 
(Table 1).  After additional SME review considering relationships highlighted by low independence scores, 
we discovered four new and two modified CFDs as shown in Table 7.  Note that although Donor CMV 
Status -> Product Type is identified as being a dependent relationship in Table 3, it does not appear in 
Table 4.  Only the 6 of 7 relationships in Table 3 where something new was found because of the methods 
in the paper are shown in Table 4.  We already knew about the Donor CMV Status -> Product Type and 
we did not find out any additional information regarding this relationship. 
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New or Modified 
Conditional 
Functional 
Dependency 
Inconsistency (CFDI) 
Rule 
Inconsistent  
Diagnosis Type -> 
Donor Relationship 
Both data elements are required.  If Diagnosis Type is “ALL CONV 
TO AML,” or “CLL,” or “CMML,” or “FANCONI’S ANEMIA” then 
Donor Relationship is not “Self”.  Certain diagnoses can be treated with 
either autologous (self) or allogeneic (non-self) donor hematopoietic 
stem cell transplants (HSCT). Other diagnoses, listed here, are not 
routinely treated with autologous donor HSCT at UMN. Therefore, self 
(autologous) donors would be unexpected for these diagnoses.    
Inconsistent  
Diagnosis Type -> 
Product Relationship  
Both data elements are required.  If Diagnosis Type is “ALL CONV 
TO AML,” or “CLL,” or “CMML,” or “FANCONI”S ANEMIA” then 
Product Relationship is not “Autologous”. See above. 
Inconsistent  
Diagnosis Type -> 
Product Type 
Both data elements are required.  If Diagnosis Type is “ALL CONV 
TO AML,” or “CLL,” or “CMML,” or “FANCONI’S ANEMIA” then 
Donor Relationship is not “Autologous Backup” or a tandem cellular 
product infusion.  The terms "Autologous Backup" or "tandem" refer to 
autologous (self) products that are collected with the intent to be used as 
a second or emergency autologous HSCT.  For example, back-to-back 
"tandem" autologous transplants are used to treat multiple 
myeloma.  They would not be used for the diagnoses listed here.  
Inconsistent  
Donor Relationship -
> 
Product Relationship 
Both data elements are required.  If Donor Relationship is "Self" 
then Product Relationship is "Autologous" and vice versa.  If Donor 
Relationship is “Identical Twin” then Product Relationship is 
“Syngeneic” and vice versa.  Any other Donor Relationship -> Product 
Relationship combination is acceptable.  Autologous product comes 
from the patient (self-donor), and similarly identical or "syngeneic" 
twins can provide allogeneic products which are characterized by 
completely identical genetics (not just identical HLA type). 
Inconsistent  
Product Type -> 
Donor Relationship 
Both data elements are required.  If Product Type is “Autologous 
Backup” or “Tandem 1st Infusion” or “Tandem 3rd Infusion” then Donor 
Relationship is “Self”.    If Product Type is “Cellerant Therapy” then 
Donor Relationship is “Unrelated”.  The same rationale is used there 
(Autologous Back up and Tandem products are from self-donors), 
whereas Cellerant products refer to an allogeneic product tested in a 
clinical trial.  
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Inconsistent  
Product Type -> 
Product Relationship 
Both data elements are required.  If Product Type is  
“Autologous Backup” then Product Relationship is Autologous."  If 
Product Type is “BMT Infusion” then Product Relationship is 
"Allogeneic".  If Product Type is any other except for “Other*” or 
“Tandem*” then Product Relationship is not "Allogeneic". 
Table 7: Highlighted are modifications to rules based on reanalysis motivated by results of 
independence testing 
 
DISCUSSION 
We set out to find what improvement, if any, was possible for rules when one adds a 
computational approach involving data profile results to SME recall.  The computational 
approach we developed first measures the percentage of independence one data element 
has from another, and based on the measure value can suggest a data rule.  The maximum 
score of 100% occurs when all the possible unique pair values are represented in the data 
set, representing non-attenuated variability, suggesting minimal relatedness and no 
associated data rule.  If half of the possible unique pair values are represented, the score 
is 50%. The minimum score of 0% occurs when only the minimum number of the 
possible unique pair values was represented in the data set. 
Because we suspected that the categorical data element pairs that seemed more 
related than not (less than 50% independent), fell into this as the result of an underlying 
data rule, these data element pairs were reanalyzed by SMEs.  The reanalysis led to the 
discovery of 4 completely new CFDs above and beyond the seven identified by initial 
SME review, and the modification of two others.  
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Our main experiment therefore provides evidence that translational cancer research 
data element instances that appear to have no CFDIs from a subject matter expert’s 
perspective can have CFDIs exposed by such computational approaches.  Our 
independence scores did not seem to occur by chance.  When independence was 
moderately low (23% to 49%), a data element pair consisting of only categorical data 
elements could be associated to a CFD and a rule could be defined for that CFD.  This 
DQ profiling appears applicable only to categorical data. 
Perhaps the combination of a computational method and SME is more powerful than 
anyone one of the methods alone, because of inherent limitations with each approach.  An 
SME is limited by the observer’s experience.  Our computational method has no such 
limitation, but instead can expose patterns without the constraint of assumptions.  Our 
computational approach, however, stops short at just exposing the patterns, rather than 
explaining why the patterns exist. The implications our results have for DQ is that a 
combination of both SME and a computational method is a beneficial approach, as each 
method compensates for the limitations of the other. 
The data set was purposefully constrained to allow testing while avoiding 
confounding the results.  This could affect applicability to broader use cases.  
Specifically, a limitation to our study is that we restricted CFD testing to only simple 
two-variable relationships.  It is not apparent that analyzing the relationship between 
combinations of greater than two data elements would provide new and non-redundant 
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information, because each relationship of such a type can often be represented by 
multiple two-variable relationships, if the distinction between transitive relationships and 
direct relationships is not important.  Consider an example where the unique values of a 
data element called Cancer Site {Ovary, Prostate, and Lung}, the unique values of a data 
element called Gender are {Female and Male}, and the unique values of a third data 
element called Has Cancer are {Yes and No}. A three-way rule is that when Cancer Site 
is {Ovary}, Has Cancer is {Yes} AND Gender is {Female}.  This is the same as having 
the first of two rules stating that when Cancer Site is {Ovary}, Has Cancer is {Yes} AND 
the second of two rules stating that when Cancer Site is {Ovary} Gender is {Female}. 
Another limitation is that the data set that we used, cellular product infusions, is not 
representative of all data.  A third limitation is that there may be other types of DQ issues 
that are not addressed by CDF (e.g. data timeliness). Future work may address these 
limitations, while building upon the work presented here. 
 
CONCLUSION 
We described a CDQ framework combining SME recall and a data profiling approach 
representing novel contextual measures for oncology research data elements.  Our 
computational approach involving data profile results added to SME recall enabled 
identification of data element pairs with moderately low independence (23% to 49%), 
and suggested relatedness if both data elements of a data element pair were categorical.  
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This in turn motivated SME reanalysis, and successfully led to an improvement in 
information about rules, proving our hypothesis. 
Note that data profiling alone does not lead to data rule definition.  The data profiling 
merely suggests relationships for an SME to subsequently explain in the form of a rule.  
Yet, for categorical data, our data profiling method combined with SME analysis was 
more effective than SME recall alone.  The combined approach exposed all rules 
involving pairs of categorical data elements that were defined initially though SME recall 
alone, in addition to rules that were not found initially. 
For non-categorical data, however, SME recall seemed superior.  The high cardinality 
of non-categorical data confounds our measure of independence, causing the approach to 
be ineffective at suggesting underlying rules. 
Using both SMEs and a data profiling approach results in the best understanding of 
rules in translational cancer research data.  Better data rules enable better definition of 
specific tests (i.e. validations and constraints) associated with data, and better 
identification of exceptions to expected conditions, which in turn enables better 
assessment of data quality. 
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CHAPTER 4: AN EFFECT OF INTEGRATION ON 
TRANSLATIONAL CANCER RESEARCH DATA QUALITY 
Giordi Orreggio, MHI1, Stuart Speedie, PhD1, Sarah Cooley, MD2  
1Institute of Health Informatics, Minneapolis, MN 
2Masonic Cancer Center, University of Minnesota, Minneapolis, MN 
 
SYNOPSIS 
Traditional data quality (DQ) efforts focus on intrinsic measures, such as accuracy 
and completeness. Translational cancer research relies heavily on integrated data 
collected longitudinally from clinical care, research subject visits, and subsequent clinical 
outcome data for required reporting.  The integration of such data potentially increases 
the ability to detect DQ issues and thereby remediating them.  Methods were developed 
to assess the DQ of 400,897 blood collection record.  This paper highlights this specific 
example to present a novel method of exposing DQ issues.  Compared to the proportion 
of DQ issues detectable (0.05% and 14.82%) in datasets representing the same body of 
blood collections but reported through two different mechanisms (HL7 and TIDE), the 
proportion detectable after integrating the two datasets (34.36%) was much greater. 
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SIGNIFICANCE 
Current DQ improvement efforts tend to focus on accuracy [9] [22] [23] and 
completeness [24][13].  Accuracy-related measures such as precision, value within range, 
and allowed values, and completeness-related measures such as missing values are 
typical measures of DQ [24][13].  We label these intrinsic measures.  Because our area of 
research, translational cancer research, relies heavily on data collected over time about 
subject visits and subsequent clinical outcomes, intrinsic data quality (IDQ) approaches 
alone that focus on individual data items independent of all others may fall short of 
characterizing the quality of the data.   
Past studies of electronic health record (EHR) data quality (DQ) have revealed highly 
variable results.  Hogan and Wagner [15] in their 1997 literature review found that the 
accuracy of data ranged between 44% and 100%, and completeness between 1.1% and 
100%, depending on the clinical concepts being studied.  In a medical setting, DQ issues 
(DQIs) may lead to decreased care quality, introduce privacy and other civil liberty 
concerns, create liability risks, undermine the reliability and benefits of information 
technology (IT) investments, deter adoption of health IT, and cost lives [16]. 
Data rules can be used to test and evaluate data quality.  Data rules provide a method 
to define specific tests (i.e. validations and constraints) associated with data, and identify 
exceptions to expected conditions.  Such rule application or tests may evaluate to a true 
or false value to set up pass or fail checks to assess DQ. They represent logical 
  
 55 
expressions that can include multiple conditional expressions, and they can contain 
simple or complex and nested Boolean conditions [21]. 
For example, when an instance of a required data element called Gender is “Male” 
and an instance of a required data element called Cancer Site is “Ovary” for the same 
patient, while the values are both valid and not missing, they are logically inconsistent 
with each other, given the rule that males are not known to have ovaries.  Chiang and 
Miller [17], and Bohannon and Fan [25] among others, call these conditional functional 
dependencies (CFDs).  They believe that in contrast to traditional functional 
dependencies (FDs) that were developed mainly for schema design, CFDs aim at 
capturing the consistency of data by incorporating bindings of semantically related 
values.  This not only yields a constraint theory for CFDs but is also a step toward a 
practical constraint-based approach for improving DQ. 
 
PREVIOUS STUDIES 
One of our previous studies compared contextual vs. intrinsic evaluation of DQ [26] 
and demonstrated that translational cancer research data element instances appearing to 
have no intrinsic data quality issues (IDQIs) could have conditional functional 
dependency inconsistencies (CFDIs), a contextual data quality issue.  To find CFDIs, we 
tested the data for conformance to data rules.  A data rule can be defined directly using 
subject matter expert (SME) recall [27]. An alternative to relying on SME recall is to 
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derive rules from data profiling results [27].  Rules regarding one data element’s 
dependency on another influence the distribution of values within the two data elements.  
This effect can be measured. 
A limitation of our two previous studies is that the data set that we used, cellular 
product infusions, was not representative of all data.  In this third study, we examine a 
different data domain, clinical lab tests, to determine more information regarding the 
applicability of our frameworks to other types of translational cancer research data.   
Information domain is not the only variable that may affect DQ.  The mechanism of 
transmission from source to recipient may also impact DQ.  With our IDQ, SME-based 
CFD, and data profiling-based CFD frameworks built, we now have measures to quantify 
this effect.  In our third study, we examine 2 sets of data each from the same source but 
differing by the mechanism of transmission.  We also examine the combined integrated 
data set.  We attempt to answer the research question, “What are the effects of 
mechanism of transmission and of integration on DQ?”  Our main experiment, therefore 
sought to explore the hypothesis that translational cancer research data element instances 
transmitted differently will have different DQIs as will integrated data element instances. 
 
CASE STUDY 
Clinical research data collection for each subject begins when a cancer patient at a 
hospital (typically at the University of Minnesota Medical Center Fairview, but 
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sometimes another institution) is enrolled as a subject in one or more clinical research 
trials.  A hospital typically collects blood samples from each patient (typically daily but 
sometimes more frequently) for testing as part of patient care and without regard to any 
research protocol.  The Cancer Center's request for an on-going HL7 feed of clinical lab 
result data from the University of Minnesota Medical Center Fairview for any Fairview 
patient who was also a Cancer Center research subject began with blood samples 
collected on 9/21/2006.  This clinical lab data from Fairview and at least one other 
organization is what we refer to as HL7.  HL7, most often white blood cell (WBC) and 
absolute lymphocyte (ALYM) results would be combined with Cancer Center research 
lab data to answer specific scientific questions asked within the context of Cancer Center 
research studies. 
On multiple occasions, however, during a review of a researcher's combined lab data, 
the researcher would discover that some clinical lab data appeared to be missing.  The 
Cancer Center had a theory that there was confusion regarding when a patient became a 
research subject, and that this led to a timing issue, which in turn lead to data failing to 
get transmitted from Fairview.  However, efforts to remediate HL7 were unsuccessful. 
Many layers of complexity exist within the Fairview clinical lab data.  We define a 
test instance as one test name per patient per physical blood collection date time.  We 
define an observation as one data entry date time when an evaluation of one test instance 
was conducted.  In many cases, a single test instance can have multiple observations 
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leading to multiple results for the same test instance.  In three specific cases, we found 
that the same observation of the blood test instance had two different results. 
In 2010, the Fairview clinical lab data became available via an additional 
system, which was then called TIDE.  TIDE would have clinical results going forward 
from that time.  TIDE also had historical data on blood collection beginning 7/25/2002, 
data preceding the HL7.  Although the source of data for both TIDE and HL7 are the 
same, the expectation was that TIDE would not have the same unexplained limitations as 
HL7. 
The next step was to validate this assumption.  In two previous health informatics 
studies, we explored an intrinsic vs. contextual data profiling, and SME versus 
computational contextual data profiling.  In this third health informatics study, we use 
these data profiling approaches to explore using the approaches to expose information 
about data quality after integrating data.  For the Cancer Center, the goal is, for time 
period that both TIDE and HL7 were available, to support the provision of the most 
complete and accurate clinical lab data whether it comes from HL7 exclusively, TIDE 
exclusively, or some combination of both. 
 
METHODS 
To setup for our comparison between TIDE and HL7, we extracted the earliest WBC 
and ALYM results found in both TIDE and HL7 (09/21/2006 5:23 PM), the latest WBC 
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and ALYM results found in both TIDE and HL7 (06/18/2014 10:59 PM), and all other 
WBC and ALYM results between the two date/times, along with each associated Patient 
ID and Collection Date Time.  The 4 data elements are described in Table 5. 
 
Data Element 
Name 
Data Element Definition 
ALYM 
Short for absolute lymphocyte count, this is a measure of the 
number of lymphocytes (a type of white blood cell) in blood.  It is 
used to evaluate and manage disorders of the blood or the 
immune system.  It is also used to evaluate and manage certain 
types of cancer and tumors Invalid source specified.. 
Collection Date 
Date sample for clinical testing was physically collected.  In 
general, if multiple samples are collected during the same date, 
only the first sample is used for the research study, as it is the 
sample that is most likely least influenced by other factors. 
Patient ID 
Each Subject's primary identifier used to link Subjects across 
data sourced from disparate systems.  It is typically but not 
always the Fairview medical record number (MRN) 
WBC 
Short for white blood cell count (leukocyte count), this is 
usually measured as part of the complete blood count (CBC). 
White blood cells are the infection-fighting cells in the blood and 
are distinct from the red (oxygen-carrying) blood cells known as 
erythrocytes. There are different types of white blood cells, 
including neutrophils (polymorphonuclear leukocytes; PMNs), 
band cells (slightly immature neutrophils), T-type lymphocytes (T 
cells), B-type lymphocytes (B cells), monocytes, eosinophils, and 
basophils. All the types of white blood cells are reflected in the 
white blood cell count. The normal range for the white blood cell 
count varies between laboratories but is usually between 4.3 and 
10.8 cells per nanoliter (nL) of blood.  A low white blood cell 
count is called leukopenia.  A high white blood cell count is 
termed Invalid source specified.. WBC can be as high as 1,052 
Invalid source specified.. 
Table 8: Data dictionary of our data extract characterizing ALYM-related data elements 
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We took several steps to aim for having no more than one result per test instance 
(with one exception noted below in Item 4): 
1. We excluded each result that was not the latest observed result for the same instance of a 
blood test. 
2. In the one case where the same ALYM observation of the same blood test instance in TIDE 
had two different results, neither matching any observation in HL7, we excluded the one 
which was associated with the inconsistent RESULT_COMPONENT_NAME (one of the 
observation record attributes) value: {Lymphocytes #}.  All other ALYM results in TIDE were 
associated with a RESULT_COMPONENT_NAME of {Absolute Lymphocytes}. 
3. In the one case where the same WBC observation of the same blood test instance in HL7 had 
two different results, neither consistent with the single observation in TIDE, we excluded the 
one which was associated with the non-numeric Result value: {Results questioned - new 
specimen has been requested}. 
4. In the one case where the same WBC observation of the same blood test instance in HL7 had 
two different results, one consistent with the single observation in TIDE and the other 
inconsistent, we excluded neither, as doing so would be utilizing knowledge that could only 
be gained by integrating the two datasets, and therefore should be included in this health 
informatics study results. 
To implement the comparison, we profiled three datasets: TIDE, HL7, and the 
combined TIDEHL7.  Per our approach described in our previous studies, after research 
and consultation with SMEs, we identified intrinsic rules and contextual rules.  We 
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associated WBC and ALYM with intrinsic rules are shown in Table 9. 
 
Intrinsic Data Quality Issue (IDQI) Rule 
Out-of-range or missing ALYM 0-1054 
Out-of-range or missing WBC 0-1054 
Table 9: Our IDQI framework applied producing of 2 intrinsic data rules  
Contextual tests included cross-checking ALYM with WBC.   ALYM is a subset of 
WBC, and therefore should be equal to or less than WBC.  Furthermore, the absence of 
WBC when ALYM exists constitutes a missing data issue.  Because ALYM results can be 
too small to report, the data element is optional. As an optional data element, testing for 
missing data would not provide any additional information regarding IDQ.  ALYM is a 
subset of WBC, and therefore related.  Finally, in the integrated data set, we flagged any 
value for the same patient, collection date, and data element as inconsistent, if the value 
from the HL7 collection process did not match the value from the TIDE collection 
process. 
  
  
 62 
RESULTS 
Within the time frame that collection results were reported through both mechanisms, 
09/21/2006 5:23 PM through 06/18/2014 10:59PM, we found 510,396 TIDE observations 
from 5830 distinct patients.  Within the same time frame, we found 274,574 HL7 
observations from 3633 distinct patients. 
Post-integration (i.e. examining each data set having the context of the other, rather 
than examining each in a silo) the discrepancy in observation counts is reflected in three 
DQ measures of HL7: Missing HL7 WBC, Missing HL7 ALYM, and TIDE Collection 
Missing in HL7.  These measures had the greatest counts (268,205 to 268,377).  Three 
analogous measures of TIDE DQ also had high counts (32,145 to 32,556), although not 
nearly as large.  The smallest counts found post-integration were Unequal TIDE-HL7 
WBC, and Unequal TIDE-HL7 ALYM, 116 and 92 respectively. 
Other DQ measures which could be examined pre-integration remained unchanged 
post-integration.  The measures ranged from 0 for Malformed Patient ID to 4635 Out-of-
range HL7 WBCs.  Table 10 shows the DQ measures. 
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Pre-integration Post-integration 
Data Source 
1: 
TIDE 
Only 
2: 
Both 
TIDE 
and 
HL7 
3: 
HL7 Only 
1: TIDE 
Only 
2: 
Both 
TIDE 
and 
HL7 
3: 
HL7 Only 
Malformed Patient 
ID 0 0 0 0 0 0 
Out-of-range TIDE 
WBC 56 46 n/a 56 46 n/a 
Out-of-range TIDE 
ALYM 65 60 n/a 65 60 n/a 
Out-of-range HL7 
WBC n/a 99 4536 n/a 99 4536 
Out-of-range HL7 
ALYM n/a 79 3 n/a 79 3 
TIDE ALYM>WBC 49 33 0 49 33 0 
HL7 ALYM>WBC n/a 56 0 n/a 56 0 
Missing TIDE WBC 632 407 n/a 632 407 32547 
Missing TIDE 
ALYM 0 0 n/a 0 0 32145 
Missing HL7 WBC n/a 66 10 268205 66 10 
Missing HL7 
ALYM n/a 172 25859 268318 172 25859 
Unequal TIDE-HL7 
WBC n/a n/a n/a n/a 116 n/a 
Unequal TIDE-HL7 
ALYM n/a n/a n/a n/a 92 n/a 
TIDE Collection 
Missing in HL7 n/a n/a n/a 268377 0 0 
HL7 Collection 
Missing in TIDE n/a n/a n/a 0 0 32556 
Table 10: More DQI counts are available (highlighted) post data integration 
DISCUSSION 
Noteworthy DQ measures which could be calculated pre-integration 
remained unchanged post-integration  
Out-of-range issues could generally be explained, and respect to these types of issues, 
TIDE DQ was generally better than that of HL7.  All 102 Out-of-range TIDE WBCs 
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were attributable to data entry of a single code, 9999999, instead of an actual value, while 
4635 Out-of-range HL7 WBCs were attributable to data entry of 49 different text 
descriptions, instead of an actual value.  118 out of 125 Out-of-range TIDE ALYMs were 
attributable to data entry of the code, 9999999, and the other 7 to 4 other high values 
(1166 to 1683) appearing to be data entry errors for 1 patient, while 82 Out-of-range HL7 
ALYMSs were attributable to data entry of 10 different text descriptions, instead of an 
actual value. 
ALYM>WBC issues could also generally be explained.  72 of 82 TIDE 
ALYM>WBC were attributable to the Out-of-range TIDE ALYM described above.  The 
10 remaining appeared to be data entry errors of ALYM for 5 patients. 40 of 56 HL7 
ALYM>WBC were attributable to the Out-of-range HL7 ALYM described above.  The 
16 remaining were attributable to data entry of a single code, ‘(Removed)’, instead of an 
actual value for 8 patients. 
 
Noteworthy DQ measures which could be calculated only post-integration 
The measures which could be calculated pre-integration oppose the expectation that 
TIDE and HL7 reflect the same data.  A second assumption was that the TIDE data 
would be more inclusive because it would not have the same unexplained limitations as 
HL7.  The measures which could be calculated only post-integration confirmed the 
existence of limitations with the HL7 data. The discrepancy in observation counts is 
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reflected in measures of HL7 DQ -- Missing HL7 WBC, Missing HL7 ALYM, and TIDE 
Collection Missing in HL7 – informed by comparison to the TIDE data.  In this respect, 
the measures are contextual, as they could only be found only after data integration. 
If all HL7 observations were also in TIDE, we might conclude that the HL7 data was 
of lesser quality than the TIDE data because the HL7 data was less complete, and 
appropriate action would be to disregard the HL7 and regard TIDE as the source of truth.  
However, this was not the case.  Of the 274,574 HL7 observations, 32,556 from 2404 
patients were not matched in TIDE. A limitation of TIDE is also exposed and this 
limitation is reflected in analogous measures of TIDE DQ -- Missing TIDE WBC, 
Missing TIDE ALYM, and HL7 Collection Missing in TIDE – informed by comparison 
to the HL7 data.  In this respect, these measures are similarly contextual, as they could 
only be found only after data integration. 
If all 2404 patients of the HL7-only observations were not found in TIDE, we might 
explore the possibility of a patient selection error within TIDE.  Our investigation found 
that this was not the case.  2156 of the 2404 HL7 patients were also in TIDE. 
The smallest counts found post-integration were Unequal TIDE-HL7 WBC, and 
Unequal TIDE-HL7 ALYM, 116 and 92 respectively.  102 of 116 Unequal TIDE-HL7 
WBCs were attributable to either Out-of-Range WBCs, while the remaining 14 appeared 
to be true discrepancies for 7 patients.  81 of 92 Unequal TIDE-HL7 ALYMS were 
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attributable to either Out-of-Range ALYMs, while the remaining 11 appeared to be true 
discrepancies for 6 patients. 
 
CONCLUSION 
The primary goal of this study was to explore the hypothesis that translational cancer 
research data element instances transmitted differently, or integrated will have different 
DQIs.  The results of our study support this hypothesis.  Each data collection event can 
result in missing data from simply utilizing faulty inclusion or exclusion logic.  
Furthermore, our dataset transmitted through the HL7 mechanism exhibited one primary 
DQI – out of range ALYM values.  Our data transmitted though the TIDE mechanism 
also exhibited only one primary DQI, but it was a different issue – non-numeric WBC 
values.  Quality check of the integrated dataset was superior.  Not only did it reveal both 
types of DQIs, it also showed the relative contribution of each, but more importantly 
revealed a greater DQI type – missing data. 
It is possible that differences in the processing to create the TIDE data versus the HL7 
data account for the differences in the final data sets. Resolving those differences, 
however, is beyond the scope of this research, which intends to provide a way only to 
expose the differences in data sets that are believed to reflect the same information. 
Limitations to this study include using one case study, examination of a small number 
set of data elements, and the utilization of no more than three data sources.  Future work 
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may address these limitations, while building upon the work presented here.  But for 
now, it appears that DQIs within oncology data collected for during clinical treatment 
may better be detected as the level of data integration is increased. 
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CHAPTER 5: DISCUSSION 
STUDY ONE: CONTEXTUAL VS. INTRINSIC EVALUATION 
The subject of our first study was the calculation of natural killer cell counts. If the 
absolute lymphocyte count (ALYM) of a blood sample is known, and the percentage of 
those ALYMs which are natural killer (NK) cells are known, the absolute count of NK 
cells (ANK), an outcome of many oncology clinical trials, can be calculated (ANK 
[cells/uL blood] = ALYM [cells/uL blood] x % of lymphocytes which are NK cells).  NK 
cells are lymphocytes which play an important role in the innate immune response to 
infection and cancer and are studied extensively as potential therapeutic agents.  
CBCs (including ALYM and WBC) are processed in a hospital from MCC clinical 
trial subjects as part of routine patient clinical care.  Separately, immune monitoring tests 
(including %NK) are processed in MCC’s research laboratory for each of the same MCC 
clinical trial subjects as determined by a specific research protocol.  An evaluation of this 
research data would reveal that the data was complete when all results were found for all 
tests that should have been taken as specified by each test’s governing protocol. 
The major finding of this study was that our method of detecting DQ issues 
contextually exposed issues above and beyond those detected by using our intrinsic 
method.  Most records flagged contextually that were not flagged intrinsically were those 
where a %NK value existed, but an associated ALYM value did not exist.  An ALYM 
result should exist for each %NK result, because the clinical study protocol calls for each 
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of these two types of lab tests to be performed on the same blood draw.  Only after 
integrating the ALYM data with the %NK data from the research lab can this be 
evaluated in the context of ANK calculation.  Possible reasons for the missing ALYM 
values include: incorrectly entered subject identifiers in the system which sources the 
%NK values preventing a linkage the ALYM value in the clinical source, or a problem 
with the integrity of transmission of the source system to the target destination.  
 
STUDY TWO: A PROFILING VS. SME RECALL APPROACH TO DEFINING 
DATA RULES 
While Study One utilized subject matter expert (SME) recall to identify data rules, in 
Study Two we automated the process, computationally evaluating each pairing of each 
data element with every other data element. Note that such data profiling alone does not 
lead to data rule definition.  The data profiling merely may suggest relationships for an 
SME to subsequently explain in the form of a rule.  Yet, for categorical data, our data 
profiling method combined with SME analysis was more effective than SME recall 
alone. 
The combination of a computational method and SME may be more powerful than 
any one of the methods alone, because of inherent limitations with each approach.  An 
SME is limited by the observer’s experience.  Our computational method has no such 
limitation, but instead can expose patterns without the constraint of assumptions.  Our 
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computational approach, however, stops short at just exposing the patterns, rather than 
explaining why the patterns exist. The implications our results have for DQ is that a 
combination of both SME and a computational method is a beneficial approach, as each 
method compensates for the limitations of the other. 
 
STUDY THREE: AN EFFECT OF INTEGRATION 
A limitation of our two previous studies is that the data set that we used, cellular 
product infusions, was not representative of all data.  In this third study, we examine a 
different data domain, clinical lab tests, to determine more information regarding the 
applicability of our frameworks to other types of translational cancer research data.   
Information domain is not the only variable that may affect DQ.  The mechanism of 
transmission from source to recipient may also impact DQ.  With our IDQ, SME-based 
CFD, and data profiling-based CFD frameworks built, we now have measures to quantify 
this effect.  In our third study, we examine 2 sets of data each from the same source but 
differing by the mechanism of transmission.  We also examine the combined integrated 
data set.  We attempt to answer the research question: “What are the effects of 
mechanism of transmission and of integration on DQ?”  Our main experiment, therefore 
sought to explore the hypothesis that translational cancer research data element instances 
transmitted differently will have different DQIs as will integrated data element instances. 
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CONCLUSION 
STUDY ONE: CONTEXTUAL VS. INTRINSIC EVALUATION 
The primary goal of this study was to explore the hypothesis that the addition of 
contextual methods of assessing the quality of translational oncology research data is 
more effective than intrinsic methods alone.  Our results concluded that in contrast to 
intrinsic methods alone, the addition of contextual methods increases the number of DQ 
issues detected.  Furthermore, the CDQ framework captured 100% of the issues that were 
identified by the IDQ framework.  This example demonstrates that the framework can be 
applied to translational oncology research data to enhance the quality and ultimately 
support better research for the development of new treatments for cancer. 
There are limitations to this study that could have influenced our conclusion. These 
include using one case study, examining of a small number set of data elements, and the 
utilization of no more than three data sources.  However, grouping this study with the 
subsequent two studies addresses this limitation and as such our conclusion stands within 
the overall context of the studies. 
 
STUDY TWO: A PROFILING VS. SME RECALL APPROACH TO DEFINING 
DATA RULES 
Our second study provides evidence that those translational cancer research data 
element instances that are categorical but appear to have no CFDIs from a subject matter 
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expert’s perspective can have CFDIs exposed by such computational approaches. For 
non-categorical data, however, SME recall seemed superior. 
In conclusion, using both SMEs and a data profiling approach results in the best 
understanding of rules in translational cancer research data.  Better data rules enable 
better definition of specific tests (i.e. validations and constraints) associated with data, 
and better identification of exceptions to expected conditions, which in turn enables 
better assessment of data quality. 
 
STUDY THREE: AN EFFECT OF INTEGRATION 
The primary goal of this study was to explore the hypothesis that translational cancer 
research data element instances transmitted differently, or integrated will have different 
DQIs.  The results of our study support this hypothesis.  Some DQ measures could be 
calculated only post-integration, which belays any assumption that two distinct data sets 
deemed fit-for-use continues to be fit-for-use after they are combined. 
Limitations to our set of three studies overall include involving using only one 
organization, The University of Minnesota, and using only two cancer research datasets: 
a cellular product infusion dataset and a blood draw dataset.  Each dataset contained no 
more than half a dozen data elements.  Only three data sources were involved.  Our 
testing seemed applicable to one data type, specifically categorical data, more than 
others.  Finally, results were not analyzed in terms of dimensions such as time, gender, or 
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disease.  These limitations were useful in meeting the study goal of developing and 
implementing a simple and reproducible pair of DQ frameworks.  
Future work may include additional organizations to expose effects attributable to 
organizational characteristics.  Medical data other than cellular product infusion data and 
blood draw data can also be explored to potentially uncover new findings or reconfirm 
the findings detailed here, while building upon the work presented here.   
Each of these studies clarifies our understanding of different factors in improving 
cancer research data quality.  Data quality efforts are enhanced when contextual methods 
including cross-checking are added to traditional intrinsic checks such as tests for 
completeness and accuracy. Using both SMEs and a data profiling approach to review 
data results in the best understanding of rules in translational cancer research data.  Better 
data rules enable better definition of specific tests (i.e. validations and constraints) 
associated with data, and better identification of exceptions to expected conditions.  
When data integration involved, quality checking before and integration provide better 
results than quality checking before integration alone.  Applying these techniques 
together enables better assessment of data quality. 
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